BIAF has been granted a new patent
Jun 26, 2024, 10:42 PM
37.11%
What does BIAF do
bioAffinity Technologies, Inc., headquartered in San Antonio, Texas, specializes in non-invasive diagnostics and targeted treatments for early-stage cancer, particularly lung cancer, with its lead product CyPath Lung. The company, which went public on August 26, 2022, employs 14 full-time staff and advances cancer therapeutics through its subsidiary, OncoSelect Therapeutics, LLC.
BIAF filed a patent for "porphyrin compounds and compositions useful for treating cancer" on Tue, February 28, 2023. The patent was officially published on Thu, September 28, 2023.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.